



Quest Diagnostics Completes Acquisition of Focus Diagnostics, Inc., a World Leader in Infectious Disease Testing

July 5, 2006

LYNDHURST, N.J., July 5 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, has completed the previously announced acquisition of Focus Diagnostics, Inc., in a cash transaction valued at approximately \$185 million.

Focus Diagnostics is recognized worldwide for its leadership in infectious and immunologic diseases and has established a reputation for being first to introduce new assays to the market, including diagnostic tests for Lyme disease, West Nile Virus and SARS. In addition, Focus Diagnostics develops and markets diagnostic products, such as HerpeSelect(R) for Herpes Simplex Virus.

The acquisition is not expected to have a material impact on Quest Diagnostics' 2006 earnings per share, excluding anticipated charges associated with the transaction.

About Quest Diagnostics

Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its national network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative new diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at: <http://www.questdiagnostics.com>.

The statements in this press release which are not historical facts or information may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results and outcomes to be materially different. Certain of these risks and uncertainties may include, but are not limited to, competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors described in the Quest Diagnostics Incorporated 2005 Form 10-K and subsequent SEC filings.

SOURCE Quest Diagnostics Incorporated

CONTACT:

Investors: Laure Park, +1-201-393-5030;

Media: Gary Samuels, +1-201-393-5700, both for Quest Diagnostics